How are antibody drug conjugates impacting treatment options for breast cancer?

In this interview with Masakazu Toi, from the Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital (Japan), we discuss how antibody drug conjugates (ADC) are expanding treatment options for primary breast cancer, including practical guidance on ADC treatment sequencing for low-recurrence-risk patients, the promise of TOPO-1 inhibitors and recent advances in biomarker development to predict ADC efficacy. How are ADCs expanding treatment options for primary breast cancer? We have two strategies to develop new therapeutics in early breast cancer: neoadjuvant or adjuvant treatment. One is escalation, particularly for high-risk patients, and the other is de-escalation. The relatively favorable prognostic...